, with an overall rate of 0.8 BSIs per 1000 patient-days. Of BSI cases, 33% were in patients with a hematological malignancy and 15% were in patients with a solid malignancy; 26% were in patients who had undergone surgery preceding infection. Twenty-six percent of BSIs were related to intensive care, and 61% occurred in patients with a central venous catheter. Sixty-five percent of the 1621 causative organisms were gram positive, 31% were gram negative, and 4% were fungi. The most common pathogens were coagulase-negative staphylococci (31%), Escherichia coli (11%), Staphylococcus aureus (11%), and enterococci (6%). Methicillin resistance was detected in 1% of S. aureus isolates and vancomycin resistance in 1% of enterococci. The 7-day case-fatality ratio was 9% and was highest for infections caused by Candida (21%) and enterococci (18%). The overall rate of nosocomial BSIs was similar to rates in England and the United States, but S. aureus, enterococci, and fungi were less common in our study, and the prevalence of antibiotic resistance was lower.
of prevention and control [12] [13] [14] [15] . Local surveillance data are the basis for planning interventions in hospitals. The main objective of national hospital infection programs is to promote surveillance by providing a uniform approach to surveillance among participating hospitals and to offer country-specific data on nosocomial infections [16] . Nationally aggregated data also make international comparison possible. Levels of antibiotic resistance vary across Europe [11, 17] . Few systematically collected surveillance data on nosocomial infections and their causative agents from the Nordic countries and countries in which the prevalence of antimicrobial-resistant organisms is relatively low have been published.
The Finnish Hospital Infection Program was started at the end of 1997. Two surveillance modules have now been developed, including hospital-wide surveillance for nosocomial BSIs. In the present article, we report the first results, which consist of the combined data from the 4 hospitals that participated in the program for surveillance for nosocomial BSIs during 1999-2000. Case finding and definitions.
Local infection-control nurses in each hospital regularly reviewed the laboratory database for positive blood culture results. The Centers for Disease Control and Prevention definition for nosocomial BSI was used, and only laboratory-confirmed BSIs were included in the study [18] . "Primary BSI" referred to bacteremia or fungemia for which there was no documented focal source, including infections that resulted from intravenous or arterial catheter infections. "Secondary BSI" was defined as an infection that developed as a consequence of a documented infection with the same microorganism at another body site. "Polymicrobial BSI" referred to infections in which 11 microorganism was recovered from the blood within a 48-h period. Of the underlying conditions and possible risk factors, type of delivery, whether the patient was a newborn, whether a hematological or solid malignancy was present, and whether the patient had undergone organ transplantation or hemodialysis were recorded, as was the presence or absence of a central venous catheter. All patients who entered the operating room were recorded as having had surgery. Only patients who were hospitalized for at least 24 h in the intensive care unit (ICU) before the occurrence of BSI were considered to have received intensive care. All BSIs that became evident during the ICU stay or within 48 h after discharge from the ICU were considered to be related to intensive care.
Clinical information and microbiological data were recorded by the local infection-control nurses on a standardized caserecord form sent monthly to the National Public Health Institute and entered into a common database. The outcome at 7 and 28 days from the date of the first positive blood culture result for a particular patient was obtained from the national population registry by use of unique person identifiers. Patientdays and discharges, by local codes and national specialty codes, were obtained from the information technology department of each hospital.
Statistical analysis. Data were analyzed with Epi Info software (Centers for Disease Control and Prevention). Both antibiotic-resistant and intermediately susceptible organisms were considered to be resistant when resistance percentages were calculated. Univariate analysis of categorical variables was done with the x 2 test, using Yates's correction, or Fisher's exact test, as appropriate. Continuous variables were analyzed by Student's t test or by the Mann-Whitney U test, depending on the sample distribution. Feedback. Feedback was given through the project Web site, which was only accessible by use of a password given to authorized persons from the participating hospitals. Each hospital had access to its own data, and all hospitals had access to the aggregated data. Feedback included several report tables generated online from the database according to the users' search criteria (hospital, time period, and ward/specialty).
RESULTS
A total of 1477 BSIs confirmed by positive results of blood culture were identified in 1265 patients. The overall infection rate was 0.8 infections per 1000 patient-days (range, 0.4-0.9) and 2.7 infections per 1000 discharges (range, 1. were gram negative, and 4% (62) were fungi. Of the bacteria, 55 (4%) were anaerobes. The most common pathogens were coagulase-negative staphylococci (CoNS), Escherichia coli, Staphylococcus aureus, and enterococci (table 3) . Most CoNS (77%) were Staphylococcus epidermidis. Of enterococci, 59 (58%) were Enterococcus faecalis, and 40 (40%) were Enterococcus faecium. After E. coli, the most common gram-negative rods were Klebsiella and Pseudomonas species. Of the 62 Candida isolates, 23 were species other than Candida albicans (8 isolates were Candida parapsilosis, 4 were Candida glabrata, 2 were Candida tropicalis, and 9 were nonspeciated Candida strains). The estimate for the proportion of non-albicans Candida species varies from 23% to 37%, depending on whether the 9 nonspeciated Candida isolates are included.
CoNS were the most common pathogens in all patient groups, except in obstetric patients, among whom S. aureus was equally common. Group B streptococci were common among newborns (17% of the microorganisms causing BSI among newborns vs. 1% among other patients; ), and P ! .01 viridans streptococci were common among patients with hematological malignancy (11% among patients with hematological malignancy vs. 3% among other patients;
). Can-P ! .01 dida species were more likely to cause BSIs in newborns (10% among newborns vs. 3% among other patients;
) and P ! .01 patients in the ICU (10% among patients in the ICU vs. 2% among other patients;
). Among patients with hemato-P ! .01 logical malignancies, S. aureus (5% of isolates) and Candida species (2% of isolates) were rare.
Resistance to methicillin was detected in 1% of S. aureus and 76% of CoNS isolates (table 4) . Among enterococci, the proportion of vancomycin-resistant isolates was 1%. Among viridans streptococci, the proportion of penicillin-resistant isolates was 24%. Approximately one-third of Pseudomonas aeruginosa isolates were resistant to piperacillin/tazobactam, one-third to ciprofloxacin, one-third to tobramycin, 12% to imipenem, and 11% to ceftazidime. When the resistance to ceftazidime was used as a marker for the potential presence of extended-spectrum b-lactamases, 2% of E. coli and 0% of Klebsiella isolates were potential carriers of these enzymes. Information about outcome was available for 97% of patients. Among those patients, 123 (9%) died within 1 week after the onset of BSI, and 232 (16%) died within 1 month. The casefatality ratios were highest for infections caused by Candida and those caused by enterococci (table 3) . The patients who died were significantly older (61 vs. 45 years;
) and were more P ! .01 likely to have had a solid malignancy (32% vs. 13%; ) or P ! .01 to have been admitted to the ICU (40% vs. 24%;
). P ! .01
DISCUSSION
Our surveillance focused on a single type of nosocomial infection with serious consequences: BSI [1] [2] [3] [4] [5] . In addition to being associated with significant morbidity and mortality, nosocomial BSIs are an important marker of antibiotic resistance among organisms that cause nosocomial infections.
Hospital-wide surveillance data on BSIs have been collected in England, where 61 hospitals participated in a surveillance program during 1997-1999 [19] . The overall BSI rate was similar to that in Finland; the mean rate in England was 0.6 infections per 1000 patient-days, compared with 0.4-0.9 infections per 1000 days, the rate observed in our study. In earlier reports from the United States, the rates were also similar; in 1989, the primary BSI rate varied in nonteaching hospitals from 1.3 to 2.5 infections per 1000 discharges and in teaching hospitals from 3.8 to 6.5 infections per 1000 discharges, compared with 1.3-3.1 infections per 1000 discharges in our study [7] .
In our study, BSIs caused by methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) constituted only 1% of the S. aureus and enterococcal isolates, even though 2 of the largest tertiary care hospitals in Finland were involved. In England, almost one-half of S. aureus isolates from BSIs were resistant to methicillin, and 10% of enterococcal isolates were resistant to vancomycin [19] . Furthermore, in the United States, the proportion of MRSA among S. aureus causing BSI was 29%, and the proportion of VRE among enterococci was 18% [20] . However, the prevalence of antibiotic resistance among CoNS, viridans streptococci, and Pseudomonas species in Finland was similar to or higher than that reported in the United States and England [19, 20] . The methods used for susceptibility testing by the microbiology laboratories involved in our study were standardized, as part of a separate project carried out by the Finnish Study Group for Antibiotic Resistance, before our surveillance began.
More than one-half of the causative microorganisms in our study were gram positive; this finding is similar to published results from the surveillance network of 49 US hospitals (Surveillance and Control of Pathogens of Epidemiologic Importance; SCOPE) during 1995-1998 [20] . S. aureus, enterococci, and Candida species were less common in our study than in the Unites States, but the proportions of CoNS and polymicrobial infections were similar [20] . Our maximum estimate for the proportion of nosocomial BSIs caused by Candida species other than C. albicans was smaller than that for the US hospitals (37% vs. 47%, respectively) [20] .
Unique person identifiers allowed us to retrieve comprehensive data on the outcomes of infections from the national population registry. Almost one-tenth of patients with nosocomial BSIs died within 1 week of the first positive blood culture result, and 16% died within 1 month. The case-fatality ratios were highest for infections caused by Candida species (42%) and enterococci (31%). In the US SCOPE network, the 1-month case-fatality ratio varied by microorganism, from 21% to 40%, and, in a teaching hospital in Iowa during the 1980s and 1990s, from 17% to 35% [20, 21] .
Comparison of site-specific infection rates between different hospitals is not recommended [16] . However, our feedback on the surveillance results to participating hospitals raised great interest, because no uniformly collected data on overall rates, rates by specialty, distribution of causative agents, and antibiotic-resistance patterns among causative agents for different patient groups had previously been available. The participating hospitals have had an opportunity to analyze their own data by time, place, and patient group, as well as to compare these data with the results of the aggregated data. This enables the hospitals to identify problem areas in which interventions and/ or intensified surveillance are needed.
The national hospital infection programs in many European countries and in the United States include in their surveillance, in addition to surgical-site infections, only infections in ICUs [16] . Resources can be saved by focusing the surveillance on high-risk units and procedures. Focusing also allows more exhaustive collection of data on device use for improved risk adjustment and more-reliable estimations of the effect of control interventions. On the basis of our results, the surveillance of blood culture-confirmed nosocomial BSIs and control measures should be intensified, at least in ICUs and in oncology and hematology specialties. Whether surveillance in ICUs also should cover infections that manifest in wards after patients have been discharged from ICUs requires further analysis.
In conclusion, the overall rate of nosocomial BSIs in Finnish hospitals was similar to the rates reported for other European countries and for the United States. However, the proportions of BSIs caused by S. aureus, enterococci, and yeasts were smaller, and the prevalence of antibiotic susceptibility among S. aureus and enterococci was significantly higher.
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